Stocktoria
Travere Therapeutics, Inc. TVTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2003-07-23
Travere Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M |
| R&D expense | — | — | — | $7.5M | — |
| SG&A expense | $337.2M | $264.1M | $265.5M | $197.5M | $126.3M |
| Operating income | -$62.8M | -$323.8M | -$388.1M | -$319.8M | -$199.4M |
| Interest expense | — | — | $11.3M | $11.0M | $19.7M |
| Income tax | $988,000 | $120,000 | $223,000 | $313,000 | $409,000 |
| Net income | -$25.5M | -$321.5M | -$111.4M | -$278.5M | -$180.1M |
| EPS (diluted) | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 |
| Operating cash flow | $37.8M | -$237.5M | -$325.4M | -$260.8M | -$76.2M |
| Free cash flow | — | — | -$326.0M | -$261.0M | -$81.3M |
| Cash & equivalents | $93.0M | $58.5M | $58.2M | $61.7M | $165.8M |
| Inventory | $36.2M | $41.9M | $9.4M | $4.5M | $7.3M |
| Total assets | $605.2M | $594.1M | $788.9M | $672.6M | $776.6M |
| Total liabilities | $490.4M | $535.0M | $588.1M | $629.7M | $474.5M |
| Shareholders' equity | $114.8M | $59.1M | $200.8M | $42.9M | $302.1M |
Source: SEC EDGAR filings · CIK 0001438533 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.